

# Respiratory Viruses in Luxembourg (ReViLux)

## Sentinel Network Report -Week 12

### Summary of Sentinel Network activities

At the end of week **2025/12**, the sentinel network detected a low epidemic activity, based on **5.1%** of consultations being associated with influenza-like illness. Among the specimens collected by the sentinel network over the last week, the percentage of positive tests for **Human rhinovirus** was **24.7%**, **14.6%** for **Metapneumovirus** and **11.2%** for **Influenza A**, while **SARS-CoV-2** activity was at a very low level.

In total, this season (24/25) 2,580 samples were received with 873 Influenza positive samples (389 Influenza B and 484 Influenza A). So far, 462 of the 484 Influenza A samples (95.4%) have been subtyped. Hundred and ninety five (42.2%) Influenza A samples have been subtyped as A(H1)pdm09 and 267 (57.8%) samples as A(H3) virus. Combined Influenza A and B positivity rates decreased slightly from 23.4% (2025/11) to 20.2% (2025/12), indicating slow decreasing influenza activity.

RSV continues to circulate at low level (2.2%) during week 2025/12, with 41.8% of subtype A and 58.2% subtype B cases this season (24/25).

Syndromic surveillance over the last 4 weeks (Table 1)

Week	ARI		ILI		Total consultations
	N	%	N	%	
2025/09	42	10.97	38	9.92	383
2025/10	60	16.71	34	9.47	359
2025/11	36	11.32	36	11.32	318
2025/12	70	16.28	22	5.12	430

*ARI: Acute Respiratory Infections; ILI: Influenza-Like Illness.*

---

## Sentinel Surveillance Network

The Sentinel Surveillance aims to monitor circulating respiratory viruses, from traditional ones like Influenza to more recent ones like SARS-CoV-2, and hence underpin public health actions. The Sentinel Network is a group of general practitioners and paediatricians spread across the country. They report the weekly number of patients showing symptoms suggestive of acute respiratory infection (ARI) and influenza-like illness (ILI), and those patients are then sampled and tested for a panel of respiratory viruses. The circulation of respiratory viruses in the north hemisphere is generally monitored by seasons that go from week 40 to week 20. The period between weeks 20 and 40 is usually called inter-season.

### Clinical results

Last week (**end of week 2025/12**), **5.1%** of the consultations were reported as ILI, representing a low epidemic activity for Luxembourg, according to ECDC and the Moving Epidemic Method. Over the past few weeks medium ILI rates have been observed in Luxembourg, but this week, the ILI rate fell to 5.1%, indicating reduced influenza activity.

The history of ILI consultations is displayed in figure 1, and a detailed summary of the number of ARI and ILI cases during the last four weeks is included in table 1.

### Laboratory results

In week 2025/12, the most frequently detected viruses (according to positivity rates) were **Human rhinovirus (24.7%)**, followed by **Metapneumovirus (14.6%)** and **Influenza A (11.2%)**. During week 2025/12, Influenza B decreased slightly to below 10%, Influenza A remained stable, while SARS-CoV-2 activity remained at very low level within the sentinel network. Overall Influenza positivity decreased from around 23.4% (2025/11) to 20.2% (table 2 and figure 4). An overview of the circulating viral pathogens during the current and previous inter-season is displayed in figure 2 and table 2.

More than 85% of the Influenza B cases identified this week were in children under 5 years of age, while Influenza A has been detected in all age-groups under 65 years old.

Over the last week (2025/12), RSV activity remained below 5% for three consecutive weeks. So far this season (24/25), two hundred and seventy RSV cases have been detected, including ninety seven RSV-A cases and hundred and thirty five RSV-B cases. Approximately, 55% of cases were aged 1 and 4 years (figure 3).

In total, 2580 sentinel samples have been analysed with more than 60% of samples belonging to age-group below 18 years and with 52% of female cases. Over the past week, 35% of samples were from adults over 18 years old and 2.3% from adults above 65 years old (figure 4).

Over the past 2 weeks, Human rhinovirus and Metapneumovirus were detected in all age-groups, while Adenovirus and Parainfluenza were detected predominantly in children.

Over the last 4 weeks, about 75% of all co-infections (N=41) were detected primarily in children below 5 years and 20% in children aged between 5 and 18 years. The most commonly identified combination was Human rhinovirus with Metapneumovirus. So far this season, ten patients were co-infected with Influenza A and B.




Figure 1. Percentage of patients with Influenza-like illness over the last three seasons Background colours according to intensity of circulation: baseline, low, medium, high, very high.

Table 2. Distribution of respiratory viruses detected within the Sentinel Network previous 4 weeks compared to previous year. Data for week 2025/12 not yet completely consolidated

Virus	Season 2024/25					Season 2023/24	
	Positivity Rate in %					W12	Total N (%)
	W09	W10	W11	W12	Total N (%)		
Human rhinovirus	15.9	25.0	15.0	24.7	602 (23.5)	41.7	572 (24.9)
Metapneumovirus	6.5	7.7	9.3	14.6	103 (4.0)	8.3	125 (5.4)
Influenzavirus A	19.6	16.3	10.3	11.2	484 (18.8)	5.6	388 (16.5)
Influenzavirus B	19.6	14.4	13.1	9.0	389 (15.1)	0.0	12 (0.5)
Adenovirus	4.7	9.6	10.3	5.6	164 (6.4)	16.7	125 (5.4)
Respiratory syncytial virus	5.6	4.8	1.9	2.2	270 (10.5)	0.0	212 (9.2)
Parainfluenzavirus	0.9	0.0	0.9	1.1	70 (2.7)	12.5	77 (3.4)
SARS-CoV-2	0.9	0.0	0.9	1.1	71 (2.8)	1.9	227 (9.7)

Co-detection counted once for each virus detected & N- total number of detection during season




Figure 2. Distribution of respiratory viruses detected within the Sentinel Network, by calendar week. Results from last weeks are not all yet consolidated. FLU-A: Influenzavirus A; FLU-B: Influenzavirus B; PIV: Parainfluenzavirus; RSV: Respiratory syncytial virus; ADV: Adenovirus; MPV: Metapneumovirus; HRV: Human rhinovirus; SC2: SARS-CoV-2.

Figure 3. Displays RSV cases according to different age groups with highest impact among the 1 years old. Data for week 2025/12 not yet completely consolidated




Figure 4. Displays number of sentinel samples received per week by age-group including overall sample positivity including Human rhinovirus (HRV, dotted line), excluding HRV (black line) and Influenza combined (red). Secondary axis corresponds to positivity





Figure 5. Displays detection of Influenza subtypes by age-group. Data for week 2025/12 not yet completely consolidated



## References

European Centre for Disease Prevention and Control. SARS-CoV-2 variants of concern. Retrieved 24 March 2025. from <https://www.ecdc.europa.eu/en/covid-19/variants-concern>

European Centre for Disease Prevention and Control. Communicable Disease Threats Report Week 15-21-March-2025-Week-12. Retrieved 24 March 2025. from <https://www.ecdc.europa.eu/en/publications-data/communicable-disease-threats-report-15-21-march-2025-week-12>

GISAID. EpiCoV – Pandemic coronavirus causing COVID-19. Retrieved 24 March 2025. from <https://www.gisaid.org>

GitHub - cov-lineages/pangolin: pango-designation/lineage\_notes.txt. (2025). Retrieved 24 March 2025. from [https://github.com/cov-lineages/pango-designation/blob/master/lineage\\_notes.txt](https://github.com/cov-lineages/pango-designation/blob/master/lineage_notes.txt)

Hadfield J. Megill C. Bell S. Huddleston J. Potter B. Callender C. et al. (2018). Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics*. 34(23). 4121-4123. doi: 10.1093/bioinformatics/bty407

Rambaut A. Holmes E. O’Toole Á. Hill V. McCrone J. Ruis C. et al. (2020). A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nature Microbiology*. 5(11). 1403-1407. doi: 10.1038/s41564-020-0770-5

World Health Organization. Tracking sars-cov-2 variants Retrieved 24 March 2025. from <https://www.who.int/activities/tracking-SARS-CoV-2-variants>

World Health Organization. Risk evaluation for SARS-CoV-2 Variant Under Monitoring: LP.8.1. from <https://www.who.int/publications/m/item/risk-evaluation-for-sars-cov-2-variant-under-monitoring-lp81>